Key facts
- Pfizer licensed the Chai Discovery AI platform.
- The platform will be used for Pfizer's drug discovery efforts.
- The goal is to accelerate the identification and development of new medicines.
Pfizer has entered into a licensing agreement with Chai Discovery for its AI platform. This strategic move is intended to bolster Pfizer's capabilities in discovering and developing new pharmaceutical treatments. The collaboration focuses on leveraging artificial intelligence to expedite the early stages of drug discovery, potentially leading to faster breakthroughs in medicine.